Business Wire

CA-SOLIDIGM

Share
Solidigm Introduces the D5-P5430 — A Data Center SSD with Exceptional Density, Performance, and Value

Solidigm, a leading global provider of innovative NAND flash memory solutions, is expanding its D5 Product Series with the Solidigm™ D5-P5430, a new QLC solid-state storage drive (SSD) optimized for mainstream and read-intensive workloads.

With most of today’s enterprise applications read-dominant, the D5-P5430 — a 4th gen PCIe QLC SSD — offers substantial storage density and Total Cost of Ownership (TCO) opportunities while delivering read performance that is equivalent to the most widely-adopted TLC SSDs.

The D5-P5430 is optimized for mainstream workloads (e.g., email/unified communications, decision support systems, object storage, and virtual desktop infrastructure) and read-intensive workloads (e.g., content delivery networks, data lakes/pipelines, video-on-demand). These workloads are typically 80% reads or higher and need to move massive amounts of data at high throughput.

As a drop-in replacement for TLC NAND-based PCIe-based SSDs, the D5-P5430 can reduce TCO by up to 27% for a typical object storage solution with a 1.5X increase in storage density and 18% lower energy cost. In addition, Solidigm’s newest drive can deliver up to 14% higher lifetime writes vs. leading TLC SSDs.

Important data center issues like power efficiency, edge computing, and sustainability of infrastructure, all benefit from the density of the D5-P5430, which can reduce power and cooling costs and lower the number of drives needed by up to 2x when compared to alternative solutions.

“Data centers need to store and analyze massive amounts of data with cost-effective and sustainable solutions,” said Greg Matson, VP, Strategic Planning and Marketing, Solidigm. “Solidigm’s D5-P5430 drives are ideal for this purpose, delivering high density, reduced TCO, and ‘just right’ performance for mainstream and read-intensive workloads.”

The D5-P5430 supports a wide range of 1U and 2U server and storage configurations with a broad range of capacities that support the following legacy and modern EDSFF form factors:

  • U.2 15mm 3.84 TB – 30.72 TB*
  • E1.S 9.5mm 3.84 TB – 15.36 TB
  • E3.S 7.5 mm 3.84 TB – 30.72 TB*

“Supermicro works with leading storage suppliers like Solidigm to bring the latest technology to our global customers that expect high-performance and secure storage technology,” said Vik Malyala, Managing Director and President, EMEA; SVP, WW FAE, Supermicro. “Solidigm’s new QLC-based E3.S SSD, the D5-P5430, gives customers a compelling combination of high density and efficiency for the data center infrastructure.”

*30 TB versions will be available later this year

ABOUT SOLIDIGM

Solidigm is a leading global provider of innovative NAND flash memory solutions. Solidigm technology unlocks data’s unlimited potential for customers, enabling them to fuel human advancement. Originating from the sale of Intel’s NAND and SSD business, Solidigm became a standalone U.S. subsidiary of semiconductor leader SK hynix in December 2021. Headquartered in Rancho Cordova, California, Solidigm is powered by the inventiveness of more than 2,000 employees in 13 locations worldwide. For more information, please visit solidigm.com and follow us on Twitter and LinkedIn. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. (d/b/a Solidigm).

  • All products, computer systems, dates, and figures specified are preliminary based on current expectations and are subject to change without notice.
  • Differences in hardware, software, or configuration will affect actual performance.
  • Solidigm optimizations, for Solidigm compilers or other products may not optimize to the same degree for non-Solidigm products.
  • Solidigm technologies may require enabled hardware, software, or service activation.
  • Nothing herein is intended to create any express or implied warranty.
  • The products described in this document may contain design defects or errors known as “errata,” which may cause the product to deviate from published specifications. Currently characterized errata are available on request.
  • Your costs and results may vary.
  • © Solidigm. “Solidigm” is a trademark of SK hynix NAND Product Solutions Corp. (d/b/a Solidigm). Other names and brands may be claimed as the property of others.

To learn more about Solidigm™ D5-5430 and the benefits of QLC, visit solidigm.com/qlc.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005023/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AdvanCell to participate in Jefferies Global Healthcare Conference in London11.11.2025 14:00:00 CET | Press release

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, will attend theJefferies Global Healthcare ConferenceinLondon from 17 to 20 November 2025. The AdvanCell team – Andrew Adamovich (CEO),Anna Karmann (CMO), Matthew Vincent (CBO), Simon Puttick (CSO) and Dayle Hogg (COO) - will discuss the company’s clinical and corporate progress, including the encouraging Phase 1b trial results for 212Pb-ADVC001, recently presented at ESMO, as well as the upcoming Phase 2 expansion in metastatic castration-resistant (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and progress on the company’s US expansion. “It’s an incredibly exciting time for AdvanCell,” said Andrew Adamovich, CEO of AdvanCell. “We are very encouraged by the promising Phase 1 data for ADVC001. We are expanding our US operations and manufacturing capabilities to support the next stage of development for our company, our lead asset and our pipeline. We loo

The Future Is Set for Tourism’s Next Era as the Inaugural TOURISE Summit Opens11.11.2025 13:51:00 CET | Press release

Nearly 8000 delegates register to attend the first TOURISE Summit being held 11-13 November140 global speakers set to take part With the bold ambition to rewrite the rules of travel, the inaugural TOURISE Summit under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister was officially opened today by H.E. Ahmed Al Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111716065/en/ His Excellency Ahmed Al Khateeb, Saudi Arabia's Minister of Tourism and Chairman of TOURISE, opens the inaugural TOURISE Summit in Riyadh. TOURISE ushers in a new era for global tourism, uniting ministers, delegates, and visionaries from around the world as the premier platform dedicated to shaping the future of global tourism. Taking place from November 11-13, 2025, immediately following the 50th United Nations Tourism

Riyadh Declaration on the Future of Tourism Sets 50-Year Roadmap as UN Tourism 26th General Assembly Closes in Saudi Arabia11.11.2025 13:39:00 CET | Press release

The 26th session of the UN Tourism General Assembly concluded today with the adoption of the Riyadh Declaration on the Future of Tourism, a momentous step taken by member states toward enhanced cooperation over the next 50 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111034542/en/ 26th UN Tourism General Assembly The Declaration reaffirms the Kingdom’s leadership in global tourism and its position at the heart of major, industry-changing decisions, as the ground-breaking Declaration is poised to play a central role in advancing the 2030 Agenda for Sustainable Development, emphasizing sustainability, digital innovation, AI integration, and inclusive tourism economies. The Riyadh Declaration on the Future of Tourism is a shared roadmap to guide the sector’s next half-century around sustainability, inclusion and AI-powered innovation.It underscores strengthening international cooperation, resilience, and the empower

Prokarium Appoints Ibs Mahmood as Chief Executive Officer11.11.2025 13:06:00 CET | Press release

Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the appointment of Ibs Mahmood as Chief Executive Officer (CEO). Ibs succeeds Kristen Albright, who will join the Board of Directors to continue shaping Prokarium’s strategic direction. Ibs brings 25 years as a biotechnology entrepreneur having founded and led multiple life science companies through clinical development, financing and strategic transactions, raising more than $300 million for his own ventures and over $2 billion for clients. He previously co-founded and led AMO Pharma, DrugDev and Induction Healthcare, and enjoyed senior roles at IQVIA, Abingworth, Shire Pharma and Investec. Ibs read medicine at the University of Oxford. “Ibs’ appointment marks an important step in Prokarium’s evolution. His unique blend of medical insight, entrepreneurial drive and industry experience will help us accelerate our mission to change the treatment paradigm in bladder canc

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma11.11.2025 13:00:00 CET | Press release

Promega MSI technology will aid in the identification of patients with microsatellite stable (MSS) endometrial carcinoma The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who may benefit from treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. This is the first Promega companion diagnostic to receive FDA approval. OncoMate® MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue. MSI status can be used to guide treatment decisions and support precision oncology strategies in endometrial carcinoma. “This approval underscores the critical role diagnostics play in accurately matching the right patients, at the right time with th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye